Diaphragmatic paralysis medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 66: Line 66:
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
*Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
*Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
===Diaphragmatic ===
===Diaphragmatic paralysis ===
Antiviral therapy for viral etiology of diaphragmatic paralysis:<ref name="pmid19277778">{{cite journal |vauthors=Crausman RS, Summerhill EM, McCool FD |title=Idiopathic diaphragmatic paralysis: Bell's palsy of the diaphragm? |journal=Lung |volume=187 |issue=3 |pages=153–7 |date= 2009 |pmid=19277778 |doi=10.1007/s00408-009-9140-z |url=}}</ref>
Antiviral therapy for viral etiology of diaphragmatic paralysis:<ref name="pmid19277778">{{cite journal |vauthors=Crausman RS, Summerhill EM, McCool FD |title=Idiopathic diaphragmatic paralysis: Bell's palsy of the diaphragm? |journal=Lung |volume=187 |issue=3 |pages=153–7 |date= 2009 |pmid=19277778 |doi=10.1007/s00408-009-9140-z |url=}}</ref>
*** '''Adult'''
* '''Adult'''
**** Valacyclovir 1000 mg twice daily for 1 week  
** Valacyclovir 1000 mg twice daily for 1 week
***** Preferred regimen  [[drug name]] 100 mg PO q12h for 10-21 days '''(Contraindications/specific instructions)''' 
 
***** Preferred regimen (2): [[drug name]] 500 mg PO q8h for 14-21 days
*** '''Pediatric'''
***** Preferred regimen (3): [[drug name]] 500 mg q12h for 14-21 days
***** Alternative regimen (1): [[drug name]] 500 mg PO q6h for 7–10 days 
***** Alternative regimen (2): [[drug name]] 500 mg PO q12h for 14–21 days
***** Alternative regimen (3): [[drug name]] 500 mg PO q6h for 14–21 days
*** 1.1.2 '''Pediatric'''
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
**** 1.1.2.1 (Specific population e.g. '''children < 8 years of age''')
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)   
***** Preferred regimen (1): [[drug name]] 50 mg/kg PO per day q8h (maximum, 500 mg per dose)   

Revision as of 14:29, 26 February 2018

Diaphragmatic Paralysis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Diaphragmatic Paralysis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Guidelines for Management

Case Studies

Case #1

Diaphragmatic paralysis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Diaphragmatic paralysis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Diaphragmatic paralysis medical therapy

CDC on Diaphragmatic paralysis medical therapy

Diaphragmatic paralysis medical therapy in the news

Blogs on Diaphragmatic paralysis medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Diaphragmatic paralysis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

Unilateral diaphragmatic paralysis

  • No treatment are required in unilateral diaphragmatic paralysis because most patients are asymptomatic.[1]
  • Transient ventilatory support with noninvasive positive pressure ventilation (NPPV) or invasive mechanical ventilation: it is used when patients with unilateral diaphragmatic paralysis develop acute respiratory dysfunction after general aneshesia or infections.

Bilateral diaphragmatic paralysis

  • Treatment options depends upon the severity of paralysis of the diaphragm and etiology. [2][3]
  • Ventilatory support (invasive or noninvasive)
  • Diaphragmatic pacing:
    • It is done via stimilation of the diaphragm by implanted electrodes at the level of the neck or thorax. [4]
    • It can not be done in patients with denervated diaphragams
    • Best candidates for diaphragmatic pacing are patients with high level cervical cord injury.[5]
  • Antiviral therapy:
  • Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
  • Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
  • Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
  • Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Diaphragmatic paralysis

Antiviral therapy for viral etiology of diaphragmatic paralysis:[6]

  • Adult
    • Valacyclovir 1000 mg twice daily for 1 week
      • Pediatric
        • 1.1.2.1 (Specific population e.g. children < 8 years of age)
          • Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
          • Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
          • Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
        • 1.1.2.2 (Specific population e.g. 'children < 8 years of age')
          • Preferred regimen (1): drug name 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
          • Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
    • 1.2 Specific Organ system involved 2
      • 1.2.1 Adult
        • Preferred regimen (1): drug name 500 mg PO q8h
      • 1.2.2 Pediatric
        • Preferred regimen (1): drug name 50 mg/kg/day PO q8h (maximum, 500 mg per dose)
  • 2 Stage 2 - Name of stage
    • 2.1 Specific Organ system involved 1
      Note (1):
      Note (2):
      Note (3):
      • 2.1.1 Adult
        • Parenteral regimen
          • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
          • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
          • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
        • Oral regimen
          • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
          • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
          • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
          • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
          • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
          • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
      • 2.1.2 Pediatric
        • Parenteral regimen
          • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
          • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
          • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '(Contraindications/specific instructions)'
        • Oral regimen
          • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
          • Preferred regimen (2): drug name (for children aged ≥ 8 years) 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
          • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
          • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
    • 2.2 'Other Organ system involved 2'
      Note (1):
      Note (2):
      Note (3):
      • 2.2.1 Adult
        • Parenteral regimen
          • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
          • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
          • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
        • Oral regimen
          • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
          • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
          • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
          • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
          • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
          • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
      • 2.2.2 Pediatric
        • Parenteral regimen
          • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
          • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
          • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
        • Oral regimen
          • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
          • Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
          • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
          • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
          • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
          • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)

References

  1. ↑ Easton PA, Fleetham JA, de la Rocha A, Anthonisen NR (January 1983). "Respiratory function after paralysis of the right hemidiaphragm". Am. Rev. Respir. Dis. 127 (1): 125–8. doi:10.1164/arrd.1983.127.1.125. PMID 6849536.
  2. ↑ Davis J, Goldman M, Loh L, Casson M (January 1976). "Diaphragm function and alveolar hypoventilation". Q. J. Med. 45 (177): 87–100. PMID 1062815.
  3. ↑ Gibson GJ (November 1989). "Diaphragmatic paresis: pathophysiology, clinical features, and investigation". Thorax. 44 (11): 960–70. PMC 462156. PMID 2688182.
  4. ↑ Le Pimpec-Barthes F, Legras A, Arame A, Pricopi C, Boucherie JC, Badia A, Panzini CM (April 2016). "Diaphragm pacing: the state of the art". J Thorac Dis. 8 (Suppl 4): S376–86. doi:10.21037/jtd.2016.03.97. PMC 4856845. PMID 27195135.
  5. ↑ Onders RP, Elmo M, Khansarinia S, Bowman B, Yee J, Road J, Bass B, Dunkin B, Ingvarsson PE, Oddsdóttir M (July 2009). "Complete worldwide operative experience in laparoscopic diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic lateral sclerosis patients". Surg Endosc. 23 (7): 1433–40. doi:10.1007/s00464-008-0223-3. PMID 19067067.
  6. ↑ Crausman RS, Summerhill EM, McCool FD (2009). "Idiopathic diaphragmatic paralysis: Bell's palsy of the diaphragm?". Lung. 187 (3): 153–7. doi:10.1007/s00408-009-9140-z. PMID 19277778.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Diaphragmatic_paralysis_medical_therapy&oldid=1448350"